Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$109.61M+371.07%Company Profile
- CEO
- Thomas C. Spalding Jr.
- Sector
- Financial Services
- Industry
- Asset Management - Income
- Employees
- 0
- Beta
- 0.64
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.02
Financials
Revenue
$109.61M+371.1%Net Income
$32.97M-47.4%EBITDA
$67.64M+59.8%Free Cash Flow
$68.28M+174.1%EPS (diluted)
$0.14-91.3%Shares Outstanding (diluted)
233.69M+494.7%Operating Expenses
$0.00Cash & Debt
$4.87MReturn of Capital
$97.30MDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $205.57M | $65.36M | $0.28 |
| 2024 | $204.91M | $467.63M | $2.00 |
| 2023 | $164.31M | $43.20M | $0.19 |
| 2022 | $87.77M | $-833.98M | $-3.57 |
| 2021 | $220.40M | $231.34M | $1.07 |
| 2020 | $196.07M | $102.86M | $0.49 |
| 2019 | $437.44M | $430.13M | $2.13 |
| 2018 | $-52.15M | $-59.94M | $-0.30 |
| 2017 | $96.36M | $88.23M | $0.44 |
| 2016 | $52.41M | $-5.61M | $-0.05 |
| 2015 | $41.53M | $26.50M | $0.67 |
| 2014 | $44.30M | $83.50M | $2.12 |
| 2013 | $43.89M | $-29.28M | $-0.75 |
| 2012 | $45.93M | $102.87M | $2.62 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NAD's reported EPS growth of -15.8% a year over 13 years. Historical EPS growth of -16% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.12
- Implied price
- $5.34
- Return from $10.28
- -12.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.66 — -74.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 31 | 37 | 43 | 49 | 55 |
|---|---|---|---|---|---|
| -25.0% | -27.5% | -24.9% | -22.6% | -20.5% | -18.7% |
| -20.0% | -22.7% | -19.9% | -17.4% | -15.2% | -13.3% |
| -15.0% | -17.8% | -14.9% | -12.3% | -9.9% | -7.8% |
| -10.0% | -13.0% | -9.9% | -7.1% | -4.7% | -2.4% |
| -5.0% | -8.2% | -4.9% | -1.9% | 0.6% | 3.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
90+12.50%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·3d ago·Negative
NAD: Muni Bonds Down Big, 5 Big-Yield CEFs On Sale (8%+ Yields) Municipal bonds just sold off hard over the last month, and many big-yield muni-bond CEFs (with yields over 8%) sold off even harder. This article shares data on 5 top big-yield muni-bond CEFs, with a special focus on the Nuveen Quality Municipal Income Fund. After explaining the selloff, big risks, and tax consequences (particularly related to anyone receiving Medicare or Affordable Care Act subsidies), the article concludes with a…
View source ↗ - Newsbusinesswire.com·5d ago·Negative
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better. LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of “Don't Get Old. Age Better.®,” a new brand campaign for its Niagen® (patented nicotinamide riboside, or NR) brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world cham…
View source ↗ - Newsbusinesswire.com·15d ago·Negative
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research …
View source ↗
Insider trading
Open-market buys and sells by NAD officers and directors.
- Bought
- $927k
- Sold
- $80.2m
20 trades
21 trades
- Siffermann William Abought
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/bought
- Siffermann William Abought
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/bought
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NAD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.